Rapid Micro Biosystems Inc. (Class A) (RPID) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Rapid Micro Biosystems Inc. (Class A) (NASDAQ: RPID) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.79 (-1.37% 1D, market cap $39.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RPID ranks #420 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RPID carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HBIO (Harvard Bioscience Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $40.1M) and PRPO (Precipio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -7.9%, cap $34.6M). Among the 5-stock peer group, RPID leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per RPID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001380106), Rapid Micro Biosystems Inc. (Class A) generated $33.6M in revenue (+19.7% YoY), -$47.1M in net income, and -$31.9M in free cash flow against $74.9M in total assets and $18.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While RPID currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.09) and Max Pain ($0.83) forces dealer call-delta covering toward $5.19.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Rapid Micro Biosystems Inc. (Class A) (RPID) slipped -1.37% to $0.79, trading at 2% of its 52-week range ($0.7 – $4.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Rapid Micro Biosystems (RPID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
White Brook Capital’s Q3 2026 investor letter expresses cautious optimism. Its Ethical All-Cap Strategy has outperformed, while the Small Cap Strategy has lagged because of execution delays, higher interest rates, and ma
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
LEXINGTON, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitat
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RPID today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RPID. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Rapid Micro Biosystems Inc. (Class A) (RPID) ranks #420 by composite RQD confidence (47/100, grade D) and #777 by equity capitalization ($39.6M). Within this direct 5-issuer industry benchmark cohort, RPID leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RPID
ACTIVE
Rapid Micro Biosystems Inc. (Class A) | D | 47/100 | — | — | -35.0% | -1.37% | $39.6M | Benchmark Subject |
| HBIO Harvard Bioscience Inc. | D | 44/100 | — | 57.7% | -35.0% | +4.51% | $40.1M | /hbio-vs-rpid → |
| PRPO Precipio Inc. | D- | 38/100 | — | 44.2% | -7.9% | +3.59% | $34.6M | /prpo-vs-rpid → |
| EYPT EyePoint Inc. | D- | 38/100 | — | — | -35.0% | +0.69% | $32.8M | /eypt-vs-rpid → |
| BNGO Bionano Genomics Inc. | D- | 36/100 | — | 46.3% | -35.0% | -0.41% | $16.8M | /bngo-vs-rpid → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapid Micro Biosystems Inc. (Class A) (RPID) reported GAAP revenue of $33.6M (+19.7% vs. FY2024 revenue of $28.1M , and +49.1% cumulative change since FY2023) , GAAP net income of -$47.1M, operating cash flow of -$31.1M, and free cash flow of -$31.9M (+29.9% YoY). On the balance sheet, RPID closed FY2025 with $74.9M in total assets against $18.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $33.6M | -$47.1M | -$31.1M | -$31.9M | $74.9M | $18.9M |
| FY2024 (FY) | 2024-12-31 | $28.1M | -$46.9M | -$44.2M | -$45.5M | $98.2M | $0 |
| FY2023 (FY) | 2023-12-31 | $22.5M | -$52.5M | -$45.1M | -$45.1M | — | — |
As of 2026-11-01, Rapid Micro Biosystems Inc. (Class A) (NASDAQ: RPID) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.79 (-1.37% 1D, market cap $39.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RPID ranks #420 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RPID carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HBIO (Harvard Bioscience Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $40.1M) and PRPO (Precipio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -7.9%, cap $34.6M). Among the 5-stock peer group, RPID leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per RPID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001380106), Rapid Micro Biosystems Inc. (Class A) generated $33.6M in revenue (+19.7% YoY), -$47.1M in net income, and -$31.9M in free cash flow against $74.9M in total assets and $18.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RPID last traded at $0.79 (-1.37% on volume of 192,150 shares), positioning the stock -27.52% below its 50-day simple moving average ($1.09) and -64.73% below its 200-day simple moving average ($2.24). Across its 52-week range of $0.70 to $4.94, RPID sits at the 2.1% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.89).
Why RPID Stock slipped -1.37% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.